메뉴 건너뛰기




Volumn 20, Issue 10, 2014, Pages 2751-2760

Repeatability of quantitative FDG-PET/CT and contrast- Enhanced CT in recurrent ovarian carcinoma: Test-Retest measurements for TumorFDGUptake, diameter, and volume

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT;

EID: 84901017078     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2634     Document Type: Article
Times cited : (35)

References (26)
  • 1
    • 79151478658 scopus 로고    scopus 로고
    • Cancer survival in Australia Canada Denmark Norway Sweden and the UK 1995-2007 the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data
    • Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127-38.
    • (2011) Lancet , vol.377 , pp. 127-138
    • Coleman, M.P.1    Forman, D.2    Bryant, H.3    Butler, J.4    Rachet, B.5    Maringe, C.6
  • 4
    • 84857405773 scopus 로고    scopus 로고
    • Optimal assessment of response in ovarian cancer
    • Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 2011;22 Suppl 8:viii49-viii51.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 8
    • Eisenhauer, E.A.1
  • 5
    • 84886949653 scopus 로고    scopus 로고
    • Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer
    • Buckler AJ, Schwartz LH, Petrick N, McNitt-Gray M, Zhao B, Fenimore C, et al. Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. Opt Express 2010;18:15267-82.
    • (2010) Opt Express , vol.18 , pp. 15267-15282
    • Buckler, A.J.1    Schwartz, L.H.2    Petrick, N.3    McNitt-Gray, M.4    Zhao, B.5    Fenimore, C.6
  • 6
    • 84878095934 scopus 로고    scopus 로고
    • The clinical viewpoint: Definitions, limitations of RECIST, practical considerations of measurement
    • Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013;19:2629-36.
    • (2013) Clin Cancer Res , vol.19 , pp. 2629-2636
    • Villaruz, L.C.1    Socinski, M.A.2
  • 9
    • 33745955010 scopus 로고    scopus 로고
    • Positron emission tomography as an imaging biomarker
    • Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
    • (2006) J Clin Oncol , vol.24 , pp. 3282-3292
    • Weber, W.A.1
  • 10
    • 66149139452 scopus 로고    scopus 로고
    • From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    • Wahl RL, Jacene H,Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
    • (2009) J Nucl Med , vol.50 , Issue.SUPPL. 1.
    • Wahl, R.L.1    Jacene, H.2    Kasamon, Y.3    Lodge, M.A.4
  • 11
    • 32944461277 scopus 로고    scopus 로고
    • Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    • Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
    • (2005) J Clin Oncol , vol.23 , pp. 7445-7453
    • Avril, N.1    Sassen, S.2    Schmalfeldt, B.3    Naehrig, J.4    Rutke, S.5    Weber, W.A.6
  • 13
    • 84884704277 scopus 로고    scopus 로고
    • Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-Analysis
    • Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-Analysis. Clin Breast Cancer 2013;13: 271-9.
    • (2013) Clin Breast Cancer , vol.13 , pp. 271-279
    • Mghanga, F.P.1    Lan, X.2    Bakari, K.H.3    Li, C.4    Zhang, Y.5
  • 17
    • 70349650689 scopus 로고    scopus 로고
    • Repeatability of 18F-FDG PET in a multicenter phase i study of patients with advanced gastrointestinal malignancies
    • Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, et al. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646-54.
    • (2009) J Nucl Med , vol.50 , pp. 1646-1654
    • Velasquez, L.M.1    Boellaard, R.2    Kollia, G.3    Hayes, W.4    Hoekstra, O.S.5    Lammertsma, A.A.6
  • 18
    • 84895075030 scopus 로고    scopus 로고
    • Test-retest variability of various quantitative measures to characterize tracer uptake and/or tracer uptake heterogeneity in metastasized liver for patients with colorectal carcinoma
    • van Velden FH, Nissen IA, Jongsma F, Velasquez LM, Hayes W, Lammertsma AA, et al. Test-retest variability of various quantitative measures to characterize tracer uptake and/or tracer uptake heterogeneity in metastasized liver for patients with colorectal carcinoma. Mol Imaging Biol 2014;16:13-18.
    • (2014) Mol Imaging Biol , vol.16 , pp. 13-18
    • Van Velden, F.H.1    Nissen, I.A.2    Jongsma, F.3    Velasquez, L.M.4    Hayes, W.5    Lammertsma, A.A.6
  • 21
    • 80053561888 scopus 로고    scopus 로고
    • Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
    • Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29: 3798-804.
    • (2011) J Clin Oncol , vol.29 , pp. 3798-3804
    • Ledermann, J.A.1    Hackshaw, A.2    Kaye, S.3    Jayson, G.4    Gabra, H.5    McNeish, I.6
  • 22
  • 23
    • 84867034899 scopus 로고    scopus 로고
    • The changing landscape of therapeutic strategies for recurrent ovarian cancer
    • Baumann KH, Wagner U, du BA. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol 2012;8: 1135-47.
    • (2012) Future Oncol , vol.8 , pp. 1135-1147
    • Baumann, K.H.1    Wagner, U.2    Du, B.A.3
  • 24
    • 34249085905 scopus 로고    scopus 로고
    • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9.
    • (2007) J Clin Oncol , vol.25 , pp. 1753-1759
    • Choi, H.1    Charnsangavej, C.2    Faria, S.C.3    Macapinlac, H.A.4    Burgess, M.A.5    Patel, S.R.6
  • 25
    • 77956672580 scopus 로고    scopus 로고
    • A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
    • Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16: 4647-53.
    • (2010) Clin Cancer Res , vol.16 , pp. 4647-4653
    • Zhao, B.1    Oxnard, G.R.2    Moskowitz, C.S.3    Kris, M.G.4    Pao, W.5    Guo, P.6
  • 26
    • 84874267110 scopus 로고    scopus 로고
    • Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings
    • Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, et al. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med 2013;38:175-82.
    • (2013) Clin Nucl Med , vol.38 , pp. 175-182
    • Kumar, V.1    Nath, K.2    Berman, C.G.3    Kim, J.4    Tanvetyanon, T.5    Chiappori, A.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.